May 17, 2021
A de-escalation antiplatelet strategy of switching from the more-potent ticagrelor (Brilinta; AstraZeneca) to clopidogrel at 1 month after PCI for acute MI is superior to continuing on ticagrelor and aspirin in terms of net clinical benefit, according to the TALOS-AMI trial.
“This study was conducted only in South Korea. However, although the prevalence of the CYP2C19 loss-of-function allele is significantly higher in Koreans than in other ethnic groups, this study showed the clinical safety of switching in this population, suggesting the potential of applying this de-escalation strategy to other ethnic groups,” said Kiyuk Chang, MD, PhD (The Catholic University of Korea, Seoul, Republic of Korea), who presented the findings in a late-breaking clinical trial session yesterday at the American College of Cardiology 2021 Scientific Session.
Cardiovascular clinicians experienced a 38 per cent burnout as the coronavirus pandemic increased, according to a survey.Among all cardiovascular clinicians cardiologists, physician s assistants, nurse practitioners, nurses, pharmacists and .
Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure, according to a study presented at the American College of Cardiology s 70th Annual Scientific Session.
Credit: PCORI
WASHINGTON, DC People with cardiovascular disease (CVD) taking aspirin to lower their chances of suffering a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization for heart attack and stroke, whether they took a high or low dose of aspirin, according to a study presented today at ACC.21, the American College of Cardiology s 70th Annual Scientific Session and published in the
New England Journal of Medicine.
CVD and atherosclerosis, in particular, which is a narrowing and hardening of the arteries is a leading cause of death for men, women, and most racial and ethnic groups in the United States, with estimated direct costs of $214 billion, according to the American Heart Association. Millions of Americans with CVD take recommended aspirin therapy to help reduce their risk of heart attack and stroke, a decades-long practice that has, until now, lacked definitive research studying the doses that work best for patients a
E-Mail
People with extremely high levels of triglycerides (a type of fat in the blood) and a specific genetic profile saw a substantial reduction in triglycerides after taking the human monoclonal antibody evinacumab compared with those taking a placebo, in a study presented at the American College of Cardiology s 70th Annual Scientific Session.
Severe hypertriglyceridemia is a rare disorder that causes extremely high levels of triglycerides, an accumulation of fat in the blood that can lead to heart, liver and pancreatic disease. People with severe hypertriglyceridemia commonly have triglyceride levels of 1,000 mg/dL (less than 150 mg/dL is considered normal and above 200 mg/dL is considered high) that cannot be adequately controlled with dietary restrictions or available medications.